Predictive Oncology Stock Market Value
| POAI Stock | USD 1.62 0.14 9.46% |
| Symbol | Predictive |
Predictive Oncology Price To Book Ratio
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Predictive Oncology. If investors know Predictive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Predictive Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.96) | Revenue Per Share | Quarterly Revenue Growth (0.49) | Return On Assets | Return On Equity |
The market value of Predictive Oncology is measured differently than its book value, which is the value of Predictive that is recorded on the company's balance sheet. Investors also form their own opinion of Predictive Oncology's value that differs from its market value or its book value, called intrinsic value, which is Predictive Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Predictive Oncology's market value can be influenced by many factors that don't directly affect Predictive Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Predictive Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Predictive Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Predictive Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Predictive Oncology 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Predictive Oncology's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Predictive Oncology.
| 01/17/2025 |
| 02/16/2025 |
If you would invest 0.00 in Predictive Oncology on January 17, 2025 and sell it all today you would earn a total of 0.00 from holding Predictive Oncology or generate 0.0% return on investment in Predictive Oncology over 30 days. Predictive Oncology is related to or competes with GlucoTrack, Sharps Technology, Microbot Medical, Nexgel, Pro Dex, Innovative Eyewear, and JIN MEDICAL. Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artifici... More
Predictive Oncology Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Predictive Oncology's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Predictive Oncology upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 7.04 | |||
| Information Ratio | 0.158 | |||
| Maximum Drawdown | 78.21 | |||
| Value At Risk | (9.70) | |||
| Potential Upside | 15.12 |
Predictive Oncology Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Predictive Oncology's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Predictive Oncology's standard deviation. In reality, there are many statistical measures that can use Predictive Oncology historical prices to predict the future Predictive Oncology's volatility.| Risk Adjusted Performance | 0.122 | |||
| Jensen Alpha | 1.64 | |||
| Total Risk Alpha | 1.63 | |||
| Sortino Ratio | 0.2336 | |||
| Treynor Ratio | 2.19 |
Predictive Oncology Backtested Returns
Predictive Oncology is abnormally volatile given 3 months investment horizon. Predictive Oncology maintains Sharpe Ratio (i.e., Efficiency) of 0.18, which implies the firm had a 0.18 % return per unit of risk over the last 3 months. We were able to analyze thirty different technical indicators, which can help you to evaluate if expected returns of 1.91% are justified by taking the suggested risk. Use Predictive Oncology Coefficient Of Variation of 628.53, risk adjusted performance of 0.122, and Semi Deviation of 5.66 to evaluate company specific risk that cannot be diversified away. Predictive Oncology holds a performance score of 14 on a scale of zero to a hundred. The company holds a Beta of 0.75, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Predictive Oncology's returns are expected to increase less than the market. However, during the bear market, the loss of holding Predictive Oncology is expected to be smaller as well. Use Predictive Oncology semi variance, day typical price, and the relationship between the maximum drawdown and accumulation distribution , to analyze future returns on Predictive Oncology.
Auto-correlation | 0.32 |
Below average predictability
Predictive Oncology has below average predictability. Overlapping area represents the amount of predictability between Predictive Oncology time series from 17th of January 2025 to 1st of February 2025 and 1st of February 2025 to 16th of February 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Predictive Oncology price movement. The serial correlation of 0.32 indicates that nearly 32.0% of current Predictive Oncology price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.32 | |
| Spearman Rank Test | 0.13 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Predictive Oncology lagged returns against current returns
Autocorrelation, which is Predictive Oncology stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Predictive Oncology's stock expected returns. We can calculate the autocorrelation of Predictive Oncology returns to help us make a trade decision. For example, suppose you find that Predictive Oncology has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Predictive Oncology regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Predictive Oncology stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Predictive Oncology stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Predictive Oncology stock over time.
Current vs Lagged Prices |
| Timeline |
Predictive Oncology Lagged Returns
When evaluating Predictive Oncology's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Predictive Oncology stock have on its future price. Predictive Oncology autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Predictive Oncology autocorrelation shows the relationship between Predictive Oncology stock current value and its past values and can show if there is a momentum factor associated with investing in Predictive Oncology.
Regressed Prices |
| Timeline |
Currently Active Assets on Macroaxis
When determining whether Predictive Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Predictive Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Predictive Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Predictive Oncology Stock:Check out Predictive Oncology Correlation, Predictive Oncology Volatility and Predictive Oncology Alpha and Beta module to complement your research on Predictive Oncology. For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Predictive Oncology technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.